Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreightons Regulatory News (CRL)

Share Price Information for Creightons (CRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 25.00
Bid: 23.00
Ask: 27.00
Change: 0.00 (0.00%)
Spread: 4.00 (17.391%)
Open: 25.00
High: 25.00
Low: 25.00
Prev. Close: 25.00
CRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Emma Hardie, Trading in own shares & TVR

27 Sep 2022 07:00

RNS Number : 7140A
Creightons PLC
27 September 2022
 

27 September 2022

 

CREIGHTONS plc ("Creightons" or the "Company")

Update on acquisition of Emma Hardie Limited

Trading in own shares and TVR

 

Creightons plc (LSE: CRL), manufacturers of personal care, beauty, and fragrance products, announces that further to the sale and purchase agreement ("SPA") relating to the acquisition of the entire share capital of Emma Hardie Limited as announced on 28 July 2021, the Company's subsidiary Potter and Moore Limited (P&M") has now made the final payment due to be made under the SPA to the sellers, and the Company and P&M has also entered into a settlement and share buyback agreement (the "Agreement") with the sellers in respect of certain matters related to the acquisition.

Final Payments to the Sellers under the SPA

The consideration for the transaction was approximately £6.36 million, comprising £5 million in cash and the issue of 1,600,000 ordinary shares of 1p each in the Company at the volume weighted average middle market CRL quoted price for the preceding 5 Business Days of 84.78p per share ("Consideration Shares"). Under the SPA, if on the date of twelve months from completion the volume weighted average middle market quoted price of an Ordinary Share for the last 5 Business days prior to that date (as derived from the Daily Official List of London Stock Exchange Plc) were to be less than £1.25, then an additional amount would be payable to the sellers in cash equal to such difference in price multiplied by the number of Consideration Shares issued. Having calculated the amounts due in accordance with the provisions of the SPA, the Company and each of the two sellers have now agreed the due amounts to be £666,832 per seller, being a total due amount of £1,333,664. P&M has made this payment to those sellers on 26 September 2022.

The additional payments due under the SPA comprising the adjustment payment and the deferred payment amounting in aggregate to £90,336 have also now been made to the sellers and no further amount is due to be paid by the Company or by P&M under the SPA.

Separate Share Buy Back of the Consideration Shares

Separately, it has been agreed with the two sellers that the Company buy back 800,000 Consideration Shares from each of them for a consideration of £288,000, being an aggregate consideration of£576,000 (together the "Buyback"). The consideration is based on the price of 36p per ordinary share being the on-market price at the time of the transaction. The Buyback took place on 26 September 2022.

The Company intends the total of 1,600,000 re-purchased shares to be held as treasury shares.

Accordingly, following the Buyback the Company's issued share capital now consists of 68,417,983 ordinary shares with voting rights (excluding treasury shares), with 1,600,000 ordinary shares held in treasury.

The above figure of 68,417,983 may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Mr Bernard Johnson Managing Director of the Company commented:

'We are pleased to announce the finalisation of the consideration for the acquisition of Emma Hardie Limited including the share buyback. Emma Hardie represents our first premium skincare brand and we remain confident that it will deliver significant return to shareholders in the years ahead.' 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Enquiries - Analysts and Investors:

Nicholas O'Shea, Director, Creightons Plc 01733 281000

Roland Cornish / Felicity Geidt, Beaumont Cornish Limited 0207 628 3396

Press Nigel Szembel, Anagallis Communications Limited 07802 362088

nigelszembel@anagallis.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFSAALIRFIF
Date   Source Headline
15th Mar 202410:52 amRNSBlock listing Interim Review
7th Mar 20247:00 amRNSDirectorate Change
4th Dec 20237:00 amRNSHalf-year Report
27th Nov 20237:00 amRNSDirectorate Change
25th Sep 202311:50 amRNSDirector/PDMR Shareholding
15th Sep 20235:24 pmRNSBlock listing Interim Review
14th Sep 20239:52 amRNSResult of AGM
1st Sep 20235:17 pmRNSDirector/PDMR Shareholding
1st Sep 20235:05 pmRNSDirector/PDMR Shareholding
25th Aug 20233:32 pmRNSDirector/PDMR Shareholding
31st Jul 20232:53 pmRNSReplacement: Director/PDMR Shareholding
24th Jul 202311:54 amRNSDirector/PDMR Shareholding
7th Jul 20237:00 amRNSAudited preliminary results
31st Mar 202310:49 amRNSTotal Voting Rights
17th Mar 20237:00 amRNSBlock listing Interim Review
16th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Dec 202211:05 amRNSSecond Price Monitoring Extn
30th Dec 202211:00 amRNSPrice Monitoring Extension
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSHalf-year Report
29th Nov 20224:41 pmRNSSecond Price Monitoring Extn
29th Nov 20224:36 pmRNSPrice Monitoring Extension
25th Nov 20227:00 amRNSInterim Results 2022 - announcement, presentations
27th Sep 20227:00 amRNSUpdate on Emma Hardie, Trading in own shares & TVR
20th Sep 20229:22 amRNSBlock Listing Update
24th Aug 20221:01 pmRNSResult of AGM
12th Jul 20229:05 amRNSSecond Price Monitoring Extn
12th Jul 20229:00 amRNSPrice Monitoring Extension
12th Jul 20227:00 amRNSResults for year to end 31 March 2022
11th Jul 20227:00 amRNSPreliminary Results, investor/analyst presentation
4th Jul 20224:42 pmRNSTotal Voting Rights
7th Jun 20223:28 pmRNSTotal Voting Rights
3rd May 20226:09 pmRNSTotal Voting Rights
12th Apr 20224:33 pmRNSDirector/PDMR Dealing, Total Voting Rights
21st Mar 202211:37 amRNSBlock listing Interim Review
7th Mar 20229:59 amRNSTotal Voting Rights
14th Jan 20222:58 pmRNSTotal Voting Rights
30th Dec 20217:00 amRNSHalf-year Report
15th Dec 20212:52 pmRNSNotice of Interim Results & Investors Presentation
6th Dec 20215:38 pmRNSTotal Voting Rights
25th Nov 20216:18 pmRNSDirector/PDMR Shareholding and Total Voting Rights
23rd Nov 20214:49 pmRNSDirector/PDMR Shareholding
18th Nov 202111:55 amRNSDirector/PDMR Shareholding
17th Nov 20211:58 pmRNSDirector/PDMR Shareholding
15th Nov 20217:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.